The food industry is currently facing significant pressure to adapt to the rise of GLP-1 weight-loss medications. However, reports of serious safety concerns may slow the adoption of these treatments.
According to FoodNavigator Europe, users have reported severe side-effects including blindness, acute pancreatitis, and death. These risks could lead to a decrease in consumer uptake of the drugs.
Such a shift might offer a respite for food companies that are struggling to respond to the changing consumption patterns created by these medications.
